UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

DR. FALK PHARMA GMBH,
Petitioner,

v.

ELLODI PHARMACEUTICALS, L.P.,
Patent Owner.

Case No. IPR2025-00052
U.S. Patent No. 10,632,069 B2

PATENT OWNER'S UPDATED EXHIBIT LIST

Exhibit No.	Description
2001	Declaration of Isha Agarwal Pursuant to 37 CFR § 42.10(c)(2)
2002	*Reserved*
2003	*Reserved*
2004	Transcript of the August 29, 2025 Deposition of Alan F. Parr, Pharm.D., Ph.D. from Nos. IPR2025-00052, IPR2025-00054, and IPR2025-00055
2005	Iorgulescu, G., Saliva between normal and pathological. Important factors in determining systemic and oral health, Journal of Medicine and Life Vol. 2, No.3, July-September 2009, pp.303-307
2006	Miehkle, S. et al., A randomised, double-blind trial comparing budesonide formulations and dosages for short-term treatment of eosinophilic oesophagitis, Gut 0:1-10 (2015)
2007	Declaration of Martyn Christopher Davies in Support of Patent Owner's Response
2008	*Curriculum Vitae* of Martyn Christopher Davies
2009	*Reserved*
2010	Clinical Trials Study, "Efficacy, Safety, and Pharmacokinetics of APT-1011 in Subjects With Eosinophilic Esophagitis (EoE)(FLUTE)," last updated Apr. 26, 2023, https://clinicaltrials.gov/study/NCT03191864?tab=results&a=11#outcome-measures
2011	Transcript of the April 9, 2025 Deposition of Alan F. Parr, Pharm.D., Ph.D. from No. IPR2024-01197
2012	"Antrum" Definition, American Medical Dictionary: A Concise and Up-to-Date Guide to Medical Terms (1998)
2013	M.E. Aulton (Ed.), Pharmaceutics: The Science of Dosage Form Design (2d. 2002)
2014	"Lozenge" Definition, Dennis B. Worthen (ed.), Dictionary of Pharmacy (2004)
2015	*Reserved*

Exhibit No.	Description
2016	Hahm, H.A., Augsburger, L.L., Ch. 9 Orally Disintegrating Tablets and Related Tablet Formulations
2017	Ghosh, T.K. et al, Drug Delivery to the Oral Cavity Molecules to Market, Ch. 14 Quick dissolving oral dosage forms: Scientific and regulatory considerations from a clinical pharmacology and Biopharmaceutics Perspective (2005)
2018	Transcript of the August 25, 2025 deposition of Alan Parr, Pharm.D. from No. IPR2024-01197
2019	*Reserved*
2020	Cordova-Fraga T, Sosa M, Wiechers C, et al., Effects of anatomical position on esophageal transit time: a biomagnetic diagnostic tech-nique. World J Gastroenterol 14:5707–11 (2008)
2021	U.S. Patent No. 8,324,192
2022	Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, Patent and Exclusivity for: N213976, Product 001 Budesonide (Eohilia) Suspension 2mg/10ml, https://www.accessdata.fda.gov/scripts/cder/ob/patent_info.cfm?Product_No=001&Appl_No=213976&Appl_type=N
2023	Memorandum from Director Coke Morgan Stewart to Members of the Patent Trial and Appeal Board re Enforcement and Non-Waiver of 37 C.F.R. § 42.104(B)(4) and Permissible Uses of General Knowledge in Inter Partes Reviews, dated July 31, 2025
2024	*Reserved*
2025	*Reserved*
2026	*Dr. Falk Pharma GMBH v. Ellodi Pharms., L.P.*, IPR2024-01197, EX1093 (P.T.A.B July 10, 2024)
2027	Transcript from the July 2, 2025 Deposition of Martyn Christopher Davies, Ph.D. from No. IPR2024-01197
2028	U.S. Patent 9,867,780

Exhibit No.	Description
2029	Geoffrey Lee, Report on Measurement of Disintegration Time of Jorvezaa® 1 mg Schmelztabletten
2030	Jorveza® label
2031	Disclaimer of U.S. Patent No. 10,632,069

Dated: January 20, 2026

Respectfully submitted,

BY: /Sanya Sukduang/
Sanya Sukduang
Reg. No. 46,390

Counsel for Patent Owner

COOLEY LLP
ATTN: Patent Group
1299 Pennsylvania Ave., NW
Suite 700
Washington D.C. 20004
Tel: (202) 776-2982
Fax: (202) 842-7887

CERTIFICATION OF SERVICE

Pursuant to 37 C.F.R. §§42.6(e)(4)(i) *et seq.*, a complete copy of the attached **PATENT OWNER'S UPDATED EXHIBIT LIST** are being served via electronic mail on the Petitioner by serving Petitioner's counsel of record as follows:

Nathanael Luman
Eric S. Furman
Sophia F. Zahn
Jared C. Bunker
KNOBBE, MARTENS, OLSON, & BEAR, LLP
2nrl@knobbe.com
2esf@knobbe.com
2sfz@knobbe.com
2jcb@knobbe.com
BoxFalkPharma@knobbe.com

DATED: January 20, 2026

/Sanya Sukduang/
Sanya Sukduang
Reg. No. 46,390